E

A New Race to Market in Advanced Prostate Cancer

Two biotech companies are in a race to market for a novel target in advanced prostate cancer.

January 19, 2016
E

Day 3 Highlights from JP Morgan Healthcare Conference #JPM16

Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco

January 13, 2016
E

Highlights of #JPM16 Healthcare Conference Day 2

Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.

January 12, 2016
E

Highlights of #JPM16 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.

January 11, 2016
E

Is Ocular Toxicity a big deal with Denintuzumab Mafodotin SGN-CD19A? #JPM16

An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.

January 11, 2016